HK1244032A1 - 控制基因表達的天然型mirna及其用途 - Google Patents
控制基因表達的天然型mirna及其用途Info
- Publication number
- HK1244032A1 HK1244032A1 HK18103547.2A HK18103547A HK1244032A1 HK 1244032 A1 HK1244032 A1 HK 1244032A1 HK 18103547 A HK18103547 A HK 18103547A HK 1244032 A1 HK1244032 A1 HK 1244032A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- same
- gene expression
- naturally occuring
- controlling gene
- mirna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014266918 | 2014-12-27 | ||
JP2015130496 | 2015-06-29 | ||
PCT/JP2015/086378 WO2016104775A1 (ja) | 2014-12-27 | 2015-12-25 | 遺伝子発現制御のための天然型miRNAおよびその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1244032A1 true HK1244032A1 (zh) | 2018-07-27 |
Family
ID=56150787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18103547.2A HK1244032A1 (zh) | 2014-12-27 | 2018-03-14 | 控制基因表達的天然型mirna及其用途 |
Country Status (15)
Country | Link |
---|---|
US (1) | US11027023B2 (zh) |
EP (1) | EP3239297B1 (zh) |
JP (1) | JP6471176B2 (zh) |
KR (1) | KR20170098914A (zh) |
CN (1) | CN107109415B (zh) |
AU (1) | AU2015368293B2 (zh) |
BR (1) | BR112017013664A2 (zh) |
CA (1) | CA2971827A1 (zh) |
ES (1) | ES2872527T3 (zh) |
HK (1) | HK1244032A1 (zh) |
IL (1) | IL252880B (zh) |
MX (1) | MX2017008587A (zh) |
RU (1) | RU2740032C2 (zh) |
SG (1) | SG11201705223XA (zh) |
WO (1) | WO2016104775A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6486836B2 (ja) | 2013-12-26 | 2019-03-20 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックmiRNAおよびその用途 |
MX2016008518A (es) | 2013-12-27 | 2017-01-26 | Bonac Corp | Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. |
WO2016158809A1 (ja) | 2015-03-27 | 2016-10-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
BR112019014547A2 (pt) | 2017-02-06 | 2020-02-18 | Nissan Chemical Corporation | Oligonucleotídeo de fita simples |
EP3604528A4 (en) * | 2017-03-31 | 2021-01-13 | Bonac Corporation | CYCLIC NUCLEIC ACID MOLECULE HAVING A GENE EXPRESSION CONTROL FUNCTION |
JPWO2019074110A1 (ja) | 2017-10-13 | 2020-12-24 | 株式会社ボナック | 一本鎖核酸分子およびその製造方法 |
TWI830718B (zh) * | 2018-02-09 | 2024-02-01 | 日商住友化學股份有限公司 | 核酸分子之製造方法 |
CA3094303A1 (en) | 2018-03-20 | 2019-09-26 | Tokyo Institute Of Technology | Antisense oligonucleotide reduced in toxicity |
CN115490768A (zh) * | 2021-06-18 | 2022-12-20 | 佛山热休生物技术有限公司 | Col1a1的表位肽及所述表位肽与热休克蛋白的复合物 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE873543C (de) | 1942-10-28 | 1953-04-16 | Basf Ag | Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern |
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4550163A (en) | 1979-02-05 | 1985-10-29 | Abbott Laboratories | Ligand analog-irreversible enzyme inhibitor conjugates |
US20030232355A1 (en) | 1992-05-22 | 2003-12-18 | Isis Pharmaceuticals, Inc. | Double-stranded peptide nucleic acids |
US5631148A (en) | 1994-04-22 | 1997-05-20 | Chiron Corporation | Ribozymes with product ejection by strand displacement |
GB9621367D0 (en) | 1996-10-14 | 1996-12-04 | Isis Innovation | Chiral peptide nucleic acids |
US6197557B1 (en) | 1997-03-05 | 2001-03-06 | The Regents Of The University Of Michigan | Compositions and methods for analysis of nucleic acids |
EP1013770A1 (en) | 1998-12-23 | 2000-06-28 | Université Louis Pasteur de Strasbourg | Non-viral transfection vector |
FR2790757B1 (fr) | 1999-03-09 | 2003-08-01 | Bioalliance Pharma | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. |
US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
US6962906B2 (en) | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
CA2439750A1 (en) | 2001-03-09 | 2002-09-19 | Boston Probes, Inc. | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation |
CA2526831C (en) | 2001-05-18 | 2012-07-31 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US20050233455A1 (en) | 2001-10-29 | 2005-10-20 | Damha Masad J | Acyclic linker-containing oligonucleotides and uses thereof |
WO2003072745A2 (en) | 2002-02-22 | 2003-09-04 | Eshleman James R | Antigene locks and therapeutic uses thereof |
JP2005521393A (ja) | 2002-03-20 | 2005-07-21 | マサチューセッツ インスティテュート オブ テクノロジー | Hiv治療 |
BRPI0313202A8 (pt) | 2002-08-05 | 2016-08-16 | Atugen Ag | Formas adicionais para interferir com as moléculas de rna |
AU2003256857A1 (en) * | 2002-08-08 | 2004-02-25 | Dharmacon, Inc. | Short interfering rnas having a hairpin structure containing a non-nucleotide loop |
US6936651B2 (en) | 2002-12-17 | 2005-08-30 | E. I. Du Pont De Nemours And Company | Compatibility improvement in crystalline thermoplastics with mineral fillers |
AU2004227414A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
WO2004111072A2 (en) | 2003-06-12 | 2004-12-23 | Applera Corporation | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same |
WO2005047505A2 (en) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
US7595301B2 (en) | 2003-09-30 | 2009-09-29 | Anges Mg, Inc. | Staple type oligonucleotide and drug comprising the same |
US20050222009A1 (en) | 2003-10-14 | 2005-10-06 | Itschak Lamensdorf | Dual phase - PNA conjugates for the delivery of PNA through the blood brain barrier |
WO2005037317A2 (en) | 2003-10-17 | 2005-04-28 | Cornell Research Foundation, Inc. | Mast cell-derived renin |
JP2008504840A (ja) | 2004-06-30 | 2008-02-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | 非リン酸骨格結合を含むオリゴヌクレオチド |
CN102895673A (zh) | 2004-08-23 | 2013-01-30 | 西伦蒂斯私人股份公司 | 眼病的治疗 |
JP5087924B2 (ja) | 2004-08-26 | 2012-12-05 | 日本新薬株式会社 | ガラクトース誘導体、薬物担体及び医薬組成物 |
CA2594672C (en) * | 2004-08-31 | 2014-12-30 | Ana I. Jimenez | Methods and compositions to inhibit p2x7 receptor expression |
CN101076592B (zh) | 2004-10-12 | 2013-08-21 | 洛克菲勒大学 | 微小rna |
ES2503742T3 (es) * | 2004-11-12 | 2014-10-07 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
JP2008526213A (ja) | 2004-12-30 | 2008-07-24 | トッド エム. ハウザー, | 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法 |
CN101395168B (zh) | 2006-03-01 | 2011-11-16 | 日本新药株式会社 | 半乳糖衍生物、药物载体及医药组合物 |
WO2007131237A2 (en) | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of ptp1b |
US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
EP1890152A1 (en) | 2006-08-14 | 2008-02-20 | Charite Universitätsmedizin-Berlin | Determination of renin/prorenin receptor activity |
JP2008220366A (ja) | 2007-02-16 | 2008-09-25 | National Institute Of Advanced Industrial & Technology | 修飾型pna/rna複合体 |
JP5145557B2 (ja) | 2007-03-01 | 2013-02-20 | 財団法人ヒューマンサイエンス振興財団 | マイクロrnaを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物 |
BRPI0809130A8 (pt) | 2007-03-21 | 2021-11-03 | Brookhaven Science Ass Llc | Composições combinadas hairpin-antissenso e métodos para modulação da expressão |
CN101121934B (zh) | 2007-04-11 | 2011-12-07 | 哈尔滨医科大学 | 多靶点miRNA反义核苷酸的制备方法 |
JP2010525826A (ja) | 2007-05-03 | 2010-07-29 | ロゼッタ インファーマティックス エルエルシー | 癌を治療するためのmir34治療剤を含む組成物 |
JP5296328B2 (ja) | 2007-05-09 | 2013-09-25 | 独立行政法人理化学研究所 | 1本鎖環状rnaおよびその製造方法 |
WO2009023333A2 (en) | 2007-05-17 | 2009-02-19 | Baylor College Of Medicine | Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines |
JP5637533B2 (ja) | 2007-05-23 | 2014-12-10 | ジーイー ヘルスケア ダーマコン,インク. | マイクロ−rnaスキャホールドおよび非天然存在型マイクロ−rna |
CA2691617C (en) | 2007-05-31 | 2020-07-21 | University Of Iowa Research Foundation | Reduction of off-target rna interference toxicity |
US20110212075A1 (en) | 2007-06-25 | 2011-09-01 | Siemens Aktiengesellschaft | Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders |
DK2193140T3 (en) | 2007-08-27 | 2017-01-23 | Iglobe Health Inst Llc | COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS |
WO2009048932A2 (en) * | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
WO2009047362A2 (en) | 2007-10-12 | 2009-04-16 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Method for opening tight junctions |
TW200927177A (en) | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
TW200930405A (en) | 2007-11-15 | 2009-07-16 | Alcon Res Ltd | Low density lipoprotein receptor-mediated siRNA delivery |
CN101889087B (zh) | 2007-11-29 | 2013-04-03 | 苏州瑞博生物技术有限公司 | 一种干扰靶基因表达的复合分子及其制备方法 |
CA3043911A1 (en) | 2007-12-04 | 2009-07-02 | Arbutus Biopharma Corporation | Targeting lipids |
WO2009076321A2 (en) | 2007-12-07 | 2009-06-18 | Halo-Bio Rnai Therapeutics Inc. | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides |
US20110055965A1 (en) | 2008-02-15 | 2011-03-03 | Hiroshi Abe | Cycle single-stranded nucleic acid complex and method for producing the same |
JP5906508B2 (ja) | 2008-03-31 | 2016-04-20 | 国立研究開発法人産業技術総合研究所 | Rna干渉効果が高い2本鎖脂質修飾rna |
US20110172295A1 (en) | 2008-04-11 | 2011-07-14 | The University Of North Carolina At Chapel Hill | METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING |
WO2009143619A1 (en) | 2008-05-27 | 2009-12-03 | Chum | Methods of treating or preventing obesity and obesity-related hypertension |
WO2010056737A2 (en) | 2008-11-11 | 2010-05-20 | Mirna Therapeutics, Inc. | Methods and compositions involving mirnas in cancer stem cells |
WO2010058824A1 (ja) | 2008-11-19 | 2010-05-27 | 国立大学法人岐阜大学 | 間葉系細胞の分化を調節するための薬剤及びその利用 |
US8426581B2 (en) | 2009-03-27 | 2013-04-23 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of the FCεR1α gene |
CA2764158A1 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
US8871730B2 (en) * | 2009-07-13 | 2014-10-28 | Somagenics Inc. | Chemical modification of short small hairpin RNAs for inhibition of gene expression |
WO2011009624A1 (en) | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
WO2011028550A1 (en) | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Segmented micro rna mimetics |
US20110052666A1 (en) | 2009-09-03 | 2011-03-03 | Medtronic, Inc. | Compositions, Methods, and Systems for SIRNA Delivery |
EP2496268A4 (en) | 2009-11-06 | 2013-06-19 | Univ Chung Ang Ind | GENE DELIVERY SYSTEMS BASED ON NANOPARTICLES |
AU2010330814B2 (en) | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
WO2011076873A1 (en) | 2009-12-23 | 2011-06-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Influenza targets |
CN103108642B (zh) | 2010-03-24 | 2015-09-23 | 雷克西制药公司 | 皮肤与纤维化症候中的rna干扰 |
CN101845071B (zh) | 2010-03-25 | 2012-02-01 | 北京欧凯纳斯科技有限公司 | 一种2’或3’偶联氨基酸的核苷衍生物、其制备方法及应用 |
JP5555940B2 (ja) | 2010-04-14 | 2014-07-23 | 国立大学法人佐賀大学 | 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法 |
JP5892608B2 (ja) | 2010-04-19 | 2016-03-23 | 国立研究開発法人理化学研究所 | 機能性核酸の安定化法 |
AU2011242576B2 (en) | 2010-04-23 | 2016-03-31 | Cold Spring Harbor Laboratory | Novel structurally designed shRNAs |
TWI527901B (zh) | 2010-07-08 | 2016-04-01 | Bonac Corp | A single stranded nucleic acid molecule used to control gene expression |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
WO2012012676A2 (en) | 2010-07-22 | 2012-01-26 | The University Of North Carolina At Chapel Hill | Use of mir-29 for cell protection |
US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
CN103052711B (zh) * | 2010-08-03 | 2016-08-03 | 株式会社博纳克 | 具有含氮脂环式骨架的单链核酸分子 |
WO2012030683A2 (en) | 2010-08-31 | 2012-03-08 | Merck Sharp & Dohme Corp. | Novel single chemical entities and methods for delivery of oligonucleotides |
TW201307376A (zh) | 2010-12-02 | 2013-02-16 | Daiichi Sankyo Co Ltd | 經修飾之單股多核苷酸 |
CN102559666B (zh) | 2010-12-18 | 2013-12-25 | 中国科学院上海生命科学研究院 | 抑制植物病毒的人工miRNA及其构建和用途 |
KR20140020900A (ko) | 2011-02-03 | 2014-02-19 | 미르나 테라퓨틱스 인코포레이티드 | Mir―34의 합성 모방체 |
CN102784398B (zh) | 2011-05-16 | 2014-06-18 | 南京大学 | 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用 |
WO2012161124A1 (ja) | 2011-05-20 | 2012-11-29 | 国立大学法人愛媛大学 | マイクロrna又はその発現系を含む組成物 |
EP2527440A1 (en) | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
JP2013055913A (ja) | 2011-09-09 | 2013-03-28 | Bonac Corp | 遺伝子発現制御のための一本鎖rna分子 |
WO2013077446A1 (ja) | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
JP2013153736A (ja) * | 2012-01-07 | 2013-08-15 | Bonac Corp | ペプチド骨格を有する一本鎖核酸分子 |
CN104039961A (zh) * | 2012-01-07 | 2014-09-10 | 株式会社博纳克 | 具有氨基酸骨架的单链核酸分子 |
US9404108B2 (en) | 2012-03-04 | 2016-08-02 | Bonac Corporation | Micro-RMA inhibitor |
AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
EP2857513A4 (en) | 2012-05-26 | 2016-05-25 | Bonac Corp | SINGLE STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING THE EXPRESSION OF A GENE HAVING AN ADMINISTRATION FUNCTION |
CA2942833A1 (en) * | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
IL293657B1 (en) | 2013-05-22 | 2024-08-01 | Alnylam Pharmaceuticals Inc | Preparations of TMPRSS6 iRNA and methods of using them |
WO2015093495A1 (ja) | 2013-12-16 | 2015-06-25 | 株式会社ボナック | TGF-β1遺伝子発現制御のための一本鎖核酸分子 |
JP6486836B2 (ja) | 2013-12-26 | 2019-03-20 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックmiRNAおよびその用途 |
MX2016008518A (es) | 2013-12-27 | 2017-01-26 | Bonac Corp | Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. |
JP6492014B2 (ja) | 2013-12-27 | 2019-03-27 | 株式会社ボナック | 遺伝子発現制御のための人工マッチ型miRNAおよびその用途 |
WO2015161255A1 (en) * | 2014-04-18 | 2015-10-22 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy |
WO2016158809A1 (ja) | 2015-03-27 | 2016-10-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
US20190010503A1 (en) | 2015-12-29 | 2019-01-10 | National University Corporation Hokkaido University | Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof |
-
2015
- 2015-12-25 EP EP15873343.6A patent/EP3239297B1/en not_active Not-in-force
- 2015-12-25 KR KR1020177020653A patent/KR20170098914A/ko not_active Application Discontinuation
- 2015-12-25 WO PCT/JP2015/086378 patent/WO2016104775A1/ja active Application Filing
- 2015-12-25 BR BR112017013664-3A patent/BR112017013664A2/pt not_active IP Right Cessation
- 2015-12-25 SG SG11201705223XA patent/SG11201705223XA/en unknown
- 2015-12-25 US US15/539,226 patent/US11027023B2/en active Active
- 2015-12-25 MX MX2017008587A patent/MX2017008587A/es unknown
- 2015-12-25 CA CA2971827A patent/CA2971827A1/en not_active Abandoned
- 2015-12-25 AU AU2015368293A patent/AU2015368293B2/en not_active Ceased
- 2015-12-25 RU RU2017126566A patent/RU2740032C2/ru active
- 2015-12-25 CN CN201580071374.5A patent/CN107109415B/zh not_active Expired - Fee Related
- 2015-12-25 ES ES15873343T patent/ES2872527T3/es active Active
- 2015-12-25 JP JP2016566558A patent/JP6471176B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-13 IL IL252880A patent/IL252880B/en active IP Right Grant
-
2018
- 2018-03-14 HK HK18103547.2A patent/HK1244032A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2740032C2 (ru) | 2020-12-30 |
CN107109415A (zh) | 2017-08-29 |
RU2017126566A (ru) | 2019-01-28 |
CN107109415B (zh) | 2021-07-09 |
US20180326091A1 (en) | 2018-11-15 |
IL252880A0 (en) | 2017-08-31 |
JP6471176B2 (ja) | 2019-02-13 |
SG11201705223XA (en) | 2017-07-28 |
RU2017126566A3 (zh) | 2019-06-06 |
WO2016104775A1 (ja) | 2016-06-30 |
AU2015368293B2 (en) | 2021-07-22 |
EP3239297A4 (en) | 2018-07-25 |
MX2017008587A (es) | 2017-10-20 |
EP3239297B1 (en) | 2021-03-10 |
CA2971827A1 (en) | 2016-06-30 |
BR112017013664A2 (pt) | 2018-03-13 |
EP3239297A1 (en) | 2017-11-01 |
US11027023B2 (en) | 2021-06-08 |
JPWO2016104775A1 (ja) | 2017-08-24 |
KR20170098914A (ko) | 2017-08-30 |
AU2015368293A1 (en) | 2017-07-13 |
ES2872527T3 (es) | 2021-11-02 |
IL252880B (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201606891B (en) | Printing system and method of controlling printing system | |
HK1244032A1 (zh) | 控制基因表達的天然型mirna及其用途 | |
EP3230473A4 (en) | Non-coding rnas and uses thereof | |
IL251468A0 (en) | aav-based gene therapy | |
EP3237017A4 (en) | Systems and methods for genome modification and regulation | |
EP3224353C0 (en) | TARGETED REMOVAL OF BACTERIAL GENES | |
IL271715B (en) | Artificial coordination type micro rna for controlling gene expression and its use | |
EP3126506A4 (en) | Gene expression system and regulation thereof | |
EP3110729A4 (en) | Backfill, methods of making, and use thereof | |
EP3158067A4 (en) | Compositions and methods for regulating gene expression via rna interference | |
GB201407322D0 (en) | Gene therapy | |
SG10201500478WA (en) | Communication apparatus, method of controlling the same, program, and computer-readable storage medium | |
HK1220015A1 (zh) | 基因測序儀的控制裝置、方法和基因測序儀 | |
IL249254A0 (en) | Gene expression system | |
PT3167068T (pt) | Controlo de processos de conversão de monóxido de carbono em biorreatores | |
EP3384921A4 (en) | NEW USE OF THIOPEPTIN | |
IL257500A (en) | Altered cullin1 gene | |
SG11201610514SA (en) | Bioreactor and uses thereof | |
EP3121282A4 (en) | Novel samdori-2 gene and use thereof | |
EP3138908A4 (en) | Novel glycosyltransferase gene and use thereof | |
IL246179B1 (en) | Parthenocarpy regulation gene and its uses | |
EP3226864A4 (en) | Methods of treating fibrosis | |
EP3194628A4 (en) | Antisense compounds and uses thereof | |
EP3226794A4 (en) | Nanoelectroablation control and vaccination | |
EP3194591A4 (en) | Antisense compounds and uses thereof |